Trials / Terminated
TerminatedNCT01994213
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
A Randomized, Single-arm, Open-label, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic Gastroenteropancreatic Neuroendocrine Tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib | Famitinib 25 mg p.o. qd |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2015-11-01
- Completion
- 2016-05-01
- First posted
- 2013-11-25
- Last updated
- 2019-01-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01994213. Inclusion in this directory is not an endorsement.